Brind.
  1. Prime Medicine, supported by the Cystic Fibrosis Foundation, achieved clinical proof-of-concept for CF treatments and plans to engage the FDA.

Foundation commits $24M for therapy development, led by David Liu and Michael P. Boyle, who is CEO of the Foundation.

1 report, 1 independent Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Foundation commits $24M for therapy development, led by David Liu and Michael P. Boyle, who is CEO of the Foundation.

Who's involved

What this event is mainly about
FoundationCystic Fibrosis FoundationDavid Liu

Keep exploring

Part of

Prime Medicine, supported by the Cystic Fibrosis Foundation, achieved clinical proof-of-concept for CF treatments and plans to engage the FDA. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireCystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy The funding will support preclinical research focused on the nonsense mutation G5